Use of HDAC inhibitors for the treatment of bone destruction

Details for Australian Patent Application No. 2008260236 (hide)

Owner Novartis AG

Inventors Growney, Joseph Daniel; Shao, Wenlin; Atadja, Peter Wisdom

Agent Davies Collison Cave

Pub. Number AU-A-2008260236

PCT Pub. Number WO2008/150782

Priority 60/940,735 30.05.07 US

Filing date 28 May 2008

Wipo publication date 11 December 2008

International Classifications

A61K 31/4045 (2006.01)

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61P 19/10 (2006.01) Drugs for skeletal disorders

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

26 November 2009 PCT application entered the National Phase

  PCT publication WO2008/150782 Priority application(s): WO2008/150782

29 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008260237-Interocclusal appliance and method

2008260233-Devices and processes for collecting and concentrating samples for microbiological analysis